Transforming growth factor-β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers

Clinical Cancer Research

Volumn 14, Issue 12, 2008, Pages 3966-3974

  Wallace, Africa ^a   Kapoor, Veena ^a   Sun, Jing ^a   Mrass, Paul ^b   Weninger, Wolfgang ^b   Heitjan, Daniel F ^a   June, Carl ^a   Kaiser, Larry R ^a   Ling, Leona E ^c   Albelda, Steven M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; GAMMA INTERFERON; MESSENGER RNA; OVALBUMIN; SM 16; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AZABICYCLO DERIVATIVE; SM16 COMPOUND;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL LINE; CELL THERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; IN VITRO STUDY; LYMPH NODE; MACROPHAGE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; THYMOMA; ADOPTIVE IMMUNOTHERAPY; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; AZABICYCLO COMPOUNDS; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 52449122955     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0356     Document Type: Article

References (56)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
2. Hinrichs CS, Gattinoni L, Restifo NP. Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol 2006;18:363-70.
3. Knutson KL,Wagner W, Disis ML. AdoptiveTcell therapy of solid cancers. Cancer Immunol Immunother 2006;55:96-103.
4. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
5. Morgan RA, Dudley ME. Wuderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
6. June C. AdoptiveT cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466-76.
7. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007;25:243-65.
8. Yee C.Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred Tcells. Proc Natl Acad Sci NAS 2002;99:16168-73.
9. Palmer DC, Balasubramaniam S, Hanada K, et al. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol 2004;173:7209-16.
10. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005;202:907-12.
11. Wang LX, Shu S, Plautz GE. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res 2005;65:9547-54.
12. Paulos CM, Wrzesinski C, Kaiser A, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ Tcells viaTLR4 signaling. J Clin Invest 2007;117:2197-204.
13. Bracci L, Moschella F, Sestili P, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007;13:644-53.
14. Lee PP Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-85.
15. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor Progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Clin Invest 2005;175:6169-76.
16. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006;29:233-40.
17. Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 2006;12:4794-803.
18. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66:5527-36.
19. de Visser KE, Kast WM. Effects of TGF-β on the immune system: implications for cancer immunotherapy. Leukemia 1999;13:1188-99.
20. Gorelik L, Flavell RA. Transforming growth factor-β in T-cell biology. Nat Rev Immunol 2002;2:46-53.
21. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-β regulation of immune responses. Annu Rev Immunol 2006;24:99-146.
22. Teicher BA. Transforming growth factor-β and the immune response to malignant disease. Clin Cancer Res 2007;13:6247-51.
23. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ Tcells correlates with Th1/Th2 phenotype. J Immunol 1998;160:5347-54.
24. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and theTh1/Th2 paradigm. J Immunol 2000;164:6166-73.
25. Rodriguez PC, Quiceno DG, Zabaleta J, et al., Arginase 1 production in the tumor microenvironment by mature myeloid cells inhibitsT-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839-49.
26. Mrass P, Weninger W. Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Immunol Rev 2006b;213:195-212.
27. Kobie JJ, Wu RS, Kurt RA, et al. Transforming growth factor β inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2006;63:1860-4.
28. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005;7:1061 -7.
29. +/CD25 Tcells into CD4+CD25+ T regulatory cells: role of tumor-derived TFG-β. J Immunol 2007;178:2883-92.
30. Chang CJ, Liao CH, Wang FH, Lin CM. Transforming growth factor-β induces apoptosis in antigen-specific CD4+ T cells prepared for adoptive immunotherapy. Immunol Lett 2003;86:37-43.
31. Thomas DA, Massague J. TGF- β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8:369-80.
32. Ahmadzadeh M, Rosenberg SA. TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 2005;174:5215-23.
33. Fu K, Corbley MJ, Sun L, et al. An orally active inhibitor of theTGF- β type i receptor, ALK5, inhibits vascular fibrosis and adventitial myofibroblast induction in the rat carotid balloon injury model. Arterioscler Thromb Vasc Biol. Epub ahead of print: 2008 Jan 17.
34. Suzuki E, Kim S, Cheung HK, et al. A novel small molecule inhibitor of TGF-β type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents the extent of tumor recurrence after surgical resection. Cancer Res 2007;67:2351-9.
35. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988;54:777-85.
36. Carbone FR, Stery SJ, Butler J, Rodda S, Moore MW. T cell receptor a-chain pairing determines the specificity of residue 262 within the Kb-restricted, ovalbumin 257-264 determinant. Int Immunol 1992;4:861-7.
37. Mrass P, Takano H, Ng LG, et al. Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med 2006a;203:2749-61
38. Huang H, Xiang J. Synergistic effect of lymphotactin and interferon-γ-inducible protein-10 transgenr expression in T-cell localization and adoptive T-cell therapy of tumors. Int J Cancer 2004;109:817-25.
39. + T-cells are the key mediators of anti-tumor effects of the vascular disrupting agent 5,6 di-methylxanthenone-4-acetic acid (DMXAA) in murine models of lung cancer and mesothelioma. Cancer Res 2005;65:11752-61.
40. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005;115:1616-26.
41. Radoja S, Sai M, Frey AB. CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J Immunol 2001;166:6074-83.
42. Radoja S, Saio M, Schaer D, et al. CD8+ Tumor-inflatingTcells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J Immunol 2001;167:5042-51.
43. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling inT cells. Nature 2001;7:1118-22.
44. Bollard CM, Rossig C, Calonge MJ, et al Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity. Blood 2002;99:3179-87.
45. Lucas PJ, McNeil N, Hilgenfeld, et al. Transforming growth factor- β pathway serves as a primary tumor suppressor in CD8+ T cell tumorgenesis. Cancer Res 2004;64:6524-9.
46. Zhang Q, Yang X, Pins M, et al. Adoptive transfer of tumor-reactive transforming growth factor-β-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res 2005;65:1761-9.
47. Lacuesta K, Buza E, Hauser H, et al. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-β receptor. J Immunother 2006;29:250-60.
48. Zhang Q, Yang X, Kundu SD, et al. Blockade of transforming growth factor-β signaling in tumorreactive CD8+ T cells activates the antitumor immune response cycle Mol Cancer Ther 2006;5:1733-43.
49. Petersen CC, Petersen MS, Agger R, Hokland ME. Accumulation in tumor tissue of adoptively transferred T cells: a comparison between intravenous and intraperitoneal injection. J Immunother 2007;29:241 - 9.
50. Kircher MR, Allport JR, Grages EE, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors Cancer Res 2003;63:6838-46.
51. Pittet MJ, Grimm J, Berger CR, et al. In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A 2007;104.12457 - 61.
52. Vicari AP, Caux C. Chemokines in cancer Cytokine Growth Factor Rev 2002;13:143-54.
53. Mantovani A, Sozzani S, Locati M, Allavena P. Sica A Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
54. Maeda H, Tsuru S. Shiraishi A. Improvement of macrophage dysfunction by administration of anti-transforming growth factor- β antibody in EL4-bearing hosts. Jpn J Cancer Res 1994;85:1137-43.
55. Yingling JM, Blanchard KL, Sawyer JS Development of TGF-β signaling inhibitors for cancer therapy Nat Rev Drug Discov 2004;3 1011 - 22.
56. Arteaga CL. Inhibition of TGFβ signaling in cancer therapy. Curr Opin Genet Dev 2006;16:30 7.